The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors
Abstract
PURPOSE: Human epidermal growth factor (HER) -mediated signaling is critical in many cancers, including subsets of breast and lung cancer. HER family members signal via the phosphatidylinositide 3-kinase (PI3K) -AKT/protein kinase B-mammalian target of rapamycin (mTOR) cascade; mTOR activation is critical for the expression of multiple contributors to tumor growth and invasion. On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors. PATIENTS AND METHODS: This study enrolled patients to dosing combinations of neratinib and temsirolimus. The primary objective was to estimate the toxicity contour of the combination and establish recommended phase II doses. RESULTS: Sixty patients were treated on 12 of 16 possible dosing combinations. Diarrhea was the most common drug-related (93%) and dose-limiting toxicity (DLT), constituting four of 10 DLTs. Dose-limiting grade 3 metabolic abnormalities were also observed. Other frequent drug-related toxicities included nausea, stomatitis (both 53%), and anemia (48%). Two maximum-tolerated dose combinations were identified: 200 mg of neratinib/25 mg of temsirolimus and 160 mg of neratinib/50 mg of temsirolimus. Responses were noted in patients with HER2-amplified breast cancer resistant to trastuzumab, HER2-mutant non-small-cell lung cancer, and tumor types without identified mutations in the HER-PI3K-mTOR pathway. CONCLUSION: The combination of neratinib and temsirolimus was tolerable and demonstrated antitumor activity in multiple tumor types, warranting further evaluation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Along the same lines, neratinib in combination with the TORC1 inhibitor temsirolimus recently demonstrated clinical activity in HER2 mutant lung cancers (Gandhi et al., 2014).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Gandhi et al., 2014
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Fiore, P. P. D., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Atkins, M. B., Hidalgo, M. M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 878
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678
Research works printed but not linked: 5
- Heinmöller P, 2003, Clin Cancer Res, 9, 5238
- Pellegrini C, 2003, Clin Cancer Res, 9, 3645
- Gandhi L, Presented at the World Conference on Lung Cancer
- Grivas PD, 2011, Am J Transl Res, 3, 362
- Gajria D, Presented at the San Antonio Breast Cancer Symposium
Cited by
Sorted by citations
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
New and emerging targeted treatments in advanced non-small-cell lung cancer
Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 497
Institutional implementation of clinical tumor profiling on an unselected cancer population
Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87062 · Cited by 450
Adaptive Randomization of Neratinib in Early Breast Cancer
Park, J. W., Liu, M., Yee, D., Yau, C. S. F., Veer, L. V. ‘., Symmans, W. F., Paoloni, M. C., Perlmutter, J., Hylton, N. M., Hogarth, M. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513750 · Cited by 456
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlési, F., Filleron, T., Dingemans, A. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 370
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 258
Peters, S., Stahel, R. A., Bubendorf, L., Bonomi, P., Villegas, A. E., Kowalski, D. M., Baik, C. S., Isla, D., de Castro, J., Garrido, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 237
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 241
Targeting mTOR and Metabolism in Cancer: Lessons and Innovations
Magaway, C., Kim, E., & Jacinto, E. (2019) · Cells · doi:10.3390/cells8121584 · Cited by 231
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
“A dose-finding study of neratinib combined with temsirolimus produced some clinical responses in HER2 mutant NSCLC patients [110].”
BackgroundErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. J. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 226
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Pillai, R. N., Behera, M., Berry, L. D., Rossi, M. R., Kris, M. G., Johnson, B. E., Bunn, P. A., Ramalingam, S. S., & Khuri, F. R. (2017) · Cancer · doi:10.1002/cncr.30869 · Cited by 216
Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C. J., Gao, G., Ng, T. L., Tu, M. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy542 · Cited by 210
Lung cancer in never smokers—the East Asian experience
Zhou, F., & Zhou, C. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.05.14 · Cited by 217
Therapeutic drug monitoring of oral targeted antineoplastic drugs
Laughlin, A. M. M., Groenland, S. L., Scherf‐Clavel, O., van Dyk, M., Huisinga, W., Michelet, R., Jaehde, U., Steeghs, N., Huitema, A. D. R., & Kloft, C. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03014-8 · Cited by 211
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C. D., & Addeo, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 210
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
Morrissey, K., Yuraszeck, T. M., Li, C., Zhang, Y., & Kasichayanula, S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12391 · Cited by 181
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
Lim, H.-J., Crowe, P., & Yang, J.-L. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1803-3 · Cited by 161
Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155
Neratinib: First Global Approval
Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0811-4 · Cited by 148
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138
Saura, C., García-Sáenz, J. Á., Xu, B., Harb, W. A., Moroose, R., Pluard, T., Cortés, J., Kiger, C., Germa, C., Wang, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3809 · Cited by 134
Xuhong, J., Qi, X., Zhang, Y., & Jiang, J. (2019) · PubMed Central · Cited by 131
Genomic alterations of ERBB receptors in cancer: clinical implications
Mishra, R., Hanker, A. B., & Garrett, J. T. (2017) · Oncotarget · doi:10.18632/oncotarget.22825 · Cited by 132
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Rothschild, S. I. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 117
Shibata, Y., & Chiba, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061424 · Cited by 112
Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Liu, S., Li, S., Hai, J., Wang, X., Chen, T., Quinn, M. M., Gao, P., Zhang, Y., Ji, H., Cross, D. A. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1875 · Cited by 114
Croessmann, S., Formisano, L., Kinch, L. N., Ericsson, P. I. G., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E., Cristofanilli, M., He, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1544 · Cited by 107
Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review
Zhao, J., & Xia, Y. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00333 · Cited by 108
The Impact of Genomic Changes on Treatment of Lung Cancer
Cardarella, S., & Johnson, B. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201305-0843pp · Cited by 103
Targeting HER2 in the treatment of non-small cell lung cancer
Mar, N., Vredenburgh, J. J., & Wasser, J. S. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.018 · Cited by 102
Bayesian optimal interval design for dose finding in drug-combination trials
Lin, R., & Yin, G. (2015) · Statistical Methods in Medical Research · doi:10.1177/0962280215594494 · Cited by 101
Profile of neratinib and its potential in the treatment of breast cancer
Kong, A. H., & Feldinger, K. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s54414 · Cited by 99
ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Chuang, J. C., Stehr, H., Liang, Y., Das, M. S., Huang, J. Q., Diehn, M., Wakelee, H. A., & Neal, J. W. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.023 · Cited by 91
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
The force of HER2 – A druggable target in NSCLC?
Jebbink, M., Langen, A. J. D., Boelens, M. C., Monkhorst, K., & Smit, E. F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101996 · Cited by 85
Chow, L. W., Xu, B., Gupta, S., Freyman, A., Zhao, Y., Abbas, R., Van, M.-L. V., & Bondarenko, I. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.178 · Cited by 84
Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer
Redig, A. J., Capelletti, M., Dahlberg, S. E., Sholl, L. M., Mach, S. L., Fontes, C., Shi, Y., Chalasani, P., & Janne, P. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2377 · Cited by 84
Lavaud, P., & André, F. (2014) · BMC Medicine · doi:10.1186/s12916-014-0132-3 · Cited by 82
Petrelli, F., Tomasello, G., Barni, S., Lonati, V., Passalacqua, R., & Ghidini, M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4419-x · Cited by 84
Ben-Baruch, N. E., Bose, R., Kavuri, S. M., Ma, C. X., & Ellis, M. J. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0131 · Cited by 79
NSCLC and HER2: between lights and shadows
Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78
Targeted therapy in NSCLC driven by HER2 insertions.
Peters, S., & Zimmermann, S. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.02.06 · Cited by 77
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Nagano, M., Kohsaka, S., Ueno, T., Kojima, S., Saka, K., Iwase, H., Kawazu, M., & Mano, H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0991 · Cited by 79
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
Melosky, B. L., Wheatley‐Price, P., Juergens, R. A., Sacher, A. G., Leighl, N. B., Tsao, M., Cheema, P. K., Snow, S. L., Liu, G., Card, P. B., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.002 · Cited by 75
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Wang, Y., Zhang, S., Wu, F., Zhao, J., Li, X., Zhao, C., Ren, S., & Zhou, C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4277-x · Cited by 70
Designs of drug-combination phase I trials in oncology: a systematic review of the literature
Riviere, M., Tourneau, C. L., Paolettí, X., Dubois, F., & Zohar, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu516 · Cited by 68
Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.576 · Cited by 62
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
Zhao, M., Scott, S. M., Evans, K. W., Yuca, E., Saridogan, T., Zheng, X., Wang, H., Korkut, A., Pico, C. X. C., Demirhan, M. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3017 · Cited by 62
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
Neratinib for HER2-positive breast cancer with an overlooked option
Guo, L., Shao, W., Zhou, C., Yang, H. J., Yang, L., Cai, Q., Wang, J., Shi, Y., Huang, L., & Zhang, J. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00736-0 · Cited by 59
Targeted therapies for advanced non-small cell lung cancer
Ai, X., Guo, X., Wang, J., Stancu, A. L., Joslin, P. M. N., Zhang, D., & Zhu, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26428 · Cited by 60
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., & Yap, T. A. (2017) · Drugs · doi:10.1007/s40265-017-0732-2 · Cited by 59
Molecular diagnostics of lung cancer in the clinic
Sholl, L. M. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.08.03 · Cited by 56
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
Eng, J., Hsu, M., Chaft, J. E., Kris, M. G., Arcila, M. E., & Li, B. T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.030 · Cited by 52
Lategahn, J., Keul, M., & Rauh, D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201710398 · Cited by 52
Austreid, E., Lønning, P. E., & Eikesdal, H. P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.885952 · Cited by 49
New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Li, X., Oprea‐Ilies, G., & Krishnamurti, U. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0288-sa · Cited by 46
Implementation of adaptive methods in early‐phase clinical trials
Petroni, G. R., Wages, N. A., Paux, G., & Dubois, F. (2016) · Statistics in Medicine · doi:10.1002/sim.6910 · Cited by 45
Ivanova, E. V., Kuraguchi, M., Xu, M., Portell, A. J., Taus, L. J., Diala, I., Lalani, A. S., Choi, J., Chambers, E. S., Li, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1844 · Cited by 45
The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials
Malley, C. O., & Pidgeon, G. P. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.11.003 · Cited by 44
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
Zer, A., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00329 · Cited by 39
Isakoff, S. J., Wang, D., Campone, M., Calles, A., Leip, E. P., Turnbull, K. W., Bardy‐Bouxin, N., Duvillié, L., & Calvo, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.508 · Cited by 38
Insertions and Deletions (Indels)
Sehn, J. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404748-8.00009-5 · Cited by 49
Brazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 37
Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
Maria, B., Sims, A. H., & Simon, P. L. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0062 · Cited by 37
The Molecular Pathology of Lung Cancer
Sholl, L. M. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.003 · Cited by 36
Corrêa, T. S., Matos, G. D. R., Segura, M., & dos Anjos, C. H. (2018) · Case Reports in Oncology · doi:10.1159/000488669 · Cited by 33
Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer
Weiler, D., Diebold, J., Strobel, K., Aebi, S. P., & Gautschi, O. P. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000424 · Cited by 32
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
Oh, I., Hur, J. Y., Park, C., Kim, Y., Kim, S. J., Lee, M. K., Kim, H. J., Lee, K. Y., Lee, J. C., & Choi, C. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.018 · Cited by 32
Boch, T., Köhler, J., Janning, M., & Loges, S. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0540 · Cited by 32
Hirakawa, A., Wages, N. A., Sato, H., & Matsui, S. (2015) · Statistics in Medicine · doi:10.1002/sim.6533 · Cited by 32
LC–MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma
Kiesel, B. F., Parise, R. A., Wong, A., Keyvanjah, K., Jacobs, S. A., & Beumer, J. H. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.11.035 · Cited by 32
Early Phase Clinical Trial Designs – State of Play and Adapting for the Future
Harrington, J., Hernandez-Guerrero, T. C., & Basu, B. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.10.005 · Cited by 31
Neratinib in HER2-Positive Breast Cancer Patients
Paranjpe, R., Basatneh, D., Tao, G., Angelis, C. D., Noormohammed, S., Ekinci, E., Abughosh, S., Ghose, R., & Trivedi, M. V. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028018824088 · Cited by 31
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00112 · Cited by 31
Kourié, H. R., Chaix, M., Gombos, A., Aftimos, P., & Awada, A. H. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1198317 · Cited by 30
Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
Muzio, L. L., Arena, C., Troiano, G., & Villa, A. (2018) · Oral Diseases · doi:10.1111/odi.12795 · Cited by 31
Neratinib for the treatment of HER2-positive early stage breast cancer
Echavarría, I., López‐Tarruella, S., Márquez‐Rodas, I., Jerez, Y., & Martín, M. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1338954 · Cited by 29
Chen, C., & Liu, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14020130 · Cited by 28
Dose-finding designs for trials of molecularly targeted agents and immunotherapies
Chiuzan, C. C., Shtaynberger, J., Manji, G. A., Duong, J., Schwartz, G. K., Ivanova, A., & Lee, S. M. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1289952 · Cited by 28
Dose-Finding Trial Designs for Combination Therapies in Oncology
Mandrekar, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9198 · Cited by 27
Cagle, P. T., Sholl, L. M., Lindeman, N. I., Alsabeh, R., Divaris, D. X. G., Foulis, P., Lee, G., Neal, J. W., Nowak, J. A., Yu, P. P., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0232-cp · Cited by 25
Brock, K., Homer, V., Soul, G., Potter, C., Chiuzan, C. C., & Lee, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08440-0 · Cited by 29
Nayak, C., & Singh, S. K. (2022) · ACS Omega · doi:10.1021/acsomega.2c01820 · Cited by 26
Sangha, R. S., Davies, A. J., Dang, N. H., Ogura, M., Macdonald, D. A., Ananthakrishnan, R., Paccagnella, M. L., Vandendries, E. R., Boni, J. P., & Goh, Y. T. (2017) · Journal of Drug Assessment · doi:10.1080/21556660.2017.1315336 · Cited by 25
Yu, Y., Byun, S., Lee, S. E., & Hong, S. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-30473-y · Cited by 25
Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?
Ge, M., Zhu, Y., Wei, M., Piao, H., & He, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188996 · Cited by 24
Ribas, R., Pancholi, S., Rani, A., Schuster, E. F., Guest, S. K., Nikitorowicz-Buniak, J., Simigdala, N., Thornhill, A. M., Avogadri-Connors, F., Cutler, R. E., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0983-1 · Cited by 24
Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Giustini, N., Jeong, A., Buturla, J. A., & Bazhenova, L. A. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.003 · Cited by 23
Biosensors, the Emerging Tools in the Identification and Detection of Cancer Markers
Islam, M. T. (2017) · Journal of Gynecology and Womens Health · doi:10.19080/jgwh.2017.05.555667 · Cited by 22
Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 21
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Sundar, R., Chénard-Poirier, M., Collins, D. C., & Yap, T. A. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00039 · Cited by 22
Effective Management and Prevention of Neratinib-Induced Diarrhea
Ustaris, F., Saura, C., Palma, J. D., Bryce, R. P., Moran, S. E., Neuman, L. L., & Ruíz, R. L. (2015) · American Journal of Hematology / Oncology® · Cited by 20
Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016
Bunn, P. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4064 · Cited by 20
Metadata
- Authors
- Gandhi, L., Bahleda, R., Tolaney, S. M., Kwak, E. L., Cleary, J. M., Pandya, S. S., Hollebecque, A., Abbas, R., Ananthakrishnan, R., Berkenblit, A., Krygowski, M., Liang, Y., Turnbull, K. W., Shapiro, G. I., & Soria, J.-C.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2014-01-10
- Volume
- 32
- Issue
- 2
- Pages
- 68-75
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113762115
- Cited by
- 198
- References
- 36
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 15 · 2020: 15 · 2019: 8 · 2018: 21 · 2017: 27 · 2016: 29 · 2015: 32 · 2014: 22
- FWCI
- 13.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neratinib, temsirolimus, HER2-positive breast cancer, HER2-mutant non-small cell lung cancer, HER2-amplified breast cancer, HER2 inhibition, mTOR inhibition, PI3K/AKT/mTOR pathway, combination therapy, dose-limiting toxicity, diarrhea, maximum tolerated dose, anticancer activity, advanced solid tumors
- MeSH terms
- Aged, Anemia, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diarrhea, Dose-Response Relationship, Drug, Female, Gene Amplification, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Nausea, Neoplasms, Quinolines, Stomatitis, Signal Transduction, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Area Under Curve, Phosphatidylinositol 3-Kinases, Sirolimus, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
